43 patients with metastatic colorectal Cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an;overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.
A phase II trial of 5- fluorouracil- folinic acid, vinorelvine in pretreated patients whith metastatic colon rectal cancer / R., Iaffaioli; G., Facchini; A., Tortoriello; F., Caponigro; G., Gesue; A., Finizio; N., Dimartino; G., Desena; B., Antonelli; G., Scaramellino; L., Fei; Santangelo, Michele; Bucci, Luigi. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - STAMPA. - 2:4(1995), pp. 513-516.
A phase II trial of 5- fluorouracil- folinic acid, vinorelvine in pretreated patients whith metastatic colon rectal cancer
SANTANGELO, MICHELE;BUCCI, LUIGI
1995
Abstract
43 patients with metastatic colorectal Cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an;overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
